X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EDP2939 is an orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of inflammatory diseases. It is being developed for the treament of psoriasis.
Lead Product(s): EDP2939
Therapeutic Area: Dermatology Product Name: EDP2939
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
The company intends to use the net proceeds to fund the completion of the Company’s ongoing Phase 2a trial of EDP2939, an investigational orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of moderate psoriasis.
Lead Product(s): EDP2939
Therapeutic Area: Dermatology Product Name: EDP2939
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Flagship Pioneering
Deal Size: $25.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 12, 2023
Details:
Evelo intends to use the net proceeds to fund the readout of its Phase 2a trial of EDP2939, an investigational orally delivered and gut-restricted bacterial extracellular vesicle, in moderate psoriasis.
Lead Product(s): EDP2939
Therapeutic Area: Dermatology Product Name: EDP2939
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BMO Capital Markets
Deal Size: $25.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 10, 2023
Details:
EDP2939 is an orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of inflammatory diseases. It is being developed for the treament of psoriasis.
Lead Product(s): EDP2939
Therapeutic Area: Dermatology Product Name: EDP2939
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
EDP1815 is an investigational orally delivered monoclonal microbial being developed for the treatment of inflammatory diseases. EDP1815 is a strain of Prevotella histicola, selected for its specific pharmacology.
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Horizon Technology Finance Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 16, 2022
Details:
The combined clinical and biomarker data presented today confirmed that our groundbreaking SINTAX-based medicine EDP1815 can resolve systemic inflammation without systemic exposure and with safety and tolerability data comparable to placebo.
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Evelo intends to use the net proceeds from the offering to continue the development of EDP1815 in a Phase 2 trial in atopic dermatitis; prepare to advance EDP1815 in registration trials in psoriasis and, upon receipt of positive Phase 2 data, atopic dermatitis.
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Flagship Pioneering
Deal Size: $79.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 25, 2022
Details:
EDP1815, is a non-live pharmaceutical preparation of a strain of Prevotella histicola was well tolerated with safety data comparable to placebo: no drug-related serious adverse events, and no meaningful difference in infections or gastrointestinal events observed.
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2022
Details:
The tolerability and safety data for EDP1815 in the trial was comparable to placebo, with the additional finding of no flare or rebound following discontinuation of therapy (which are often seen with other therapies for psoriasis).
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
Oral daily treatment with EDP1867 administered prophylactically or therapeutically reduced the severity of disease as demonstrated by a decreased mean maximum score and a decreased incidence of relapse compared to placebo.
Lead Product(s): EDP1867
Therapeutic Area: Immunology Product Name: EDP1867
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
